Immune Response Biopharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
5
Active:0
Completed:0
Trial Phases
3 Phases
Phase 1:1
Phase 2:3
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (60.0%)Phase 1
1 (20.0%)Phase 3
1 (20.0%)REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study
Phase 3
- Conditions
- HIV
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Immune Response BioPharma, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT02366026
- Locations
- 🇺🇸
Clinical Site TBA, San Diego, California, United States
REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study
Phase 2
- Conditions
- HIV/AIDS
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Immune Response BioPharma, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02291809
- Locations
- 🇺🇸
Clinical Site TBA, San Diego, California, United States
A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis
Phase 1
Not yet recruiting
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Immune Response BioPharma, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02200718
- Locations
- 🇺🇸
CRO, San Diego, California, United States
A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis
Phase 2
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Immune Response BioPharma, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT02149706
- Locations
- 🇺🇸
CRO, San Diego, California, United States
A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis
Phase 2
- Conditions
- Multiple SclerosisSecondary Progress Multiple Sclerosis
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Immune Response BioPharma, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT02057159
- Locations
- 🇺🇸
CRO, San Diego, California, United States
News
No news found